68Ga-PSMA与18F-胆碱PET/CT在前列腺癌分期/再分期中的比较:系统综述与荟萃分析
基于患者的汇总敏感度、特异度、DOR和AUC分别为0.92、0.94、79.04、0.96(PSMA)与0.93、0.83、68.27、0.95(胆碱);两种示踪剂在检测或排除前列腺癌能力上无统计学显著差异。
要点
- 68Ga-PSMA与18F-胆碱PET/CT在前列腺癌分期/再分期中诊断性能无显著差异
- 基于患者PSMA汇总敏感度0.92、特异度0.94,胆碱为0.93、0.83
- 两种示踪剂均具高诊断性能,均应考虑用于前列腺癌分期
核心结论
- 在前列腺癌分期和再分期中,68Ga-PSMA PET/CT与18F-胆碱PET/CT的诊断性能无统计学显著差异。
- 两种示踪剂均表现出高诊断性能,均应考虑用于该疾病的分期。
研究设计与样本
- 系统综述与荟萃分析,检索PubMed自建库至2018年10月1日,按PRISMA声明进行。
主要发现
- 基于患者,68Ga-PSMA PET/CT(13项研究)汇总敏感度0.92、特异度0.94、PLR 7.91、NLR 0.14、DOR 79.04、AUC 0.96。
- 基于患者,18F-胆碱PET/CT(16项研究)汇总敏感度0.93、特异度0.83、PLR 4.98、NLR 0.10、DOR 68.27、AUC 0.95。
- 基于病灶,68Ga-PSMA PET/CT(9项研究)汇总敏感度0.83、特异度0.95、PLR 23.30、NLR 0.17、DOR 153.58、AUC 0.94。
- 基于病灶,18F-胆碱PET/CT(4项研究)汇总敏感度0.81、特异度0.92、PLR 8.59、NLR 0.20、DOR 44.82、AUC 0.98。
- 基于患者和病灶的成像中,两种示踪剂检测或排除前列腺癌的能力均无统计学显著差异。
关键数值与推荐
- 基于患者68Ga-PSMA PET/CT汇总敏感度0.92、特异度0.94、AUC 0.96。
- 基于患者18F-胆碱PET/CT汇总敏感度0.93、特异度0.83、AUC 0.95。
- 基于病灶68Ga-PSMA PET/CT汇总敏感度0.83、特异度0.95、AUC 0.94。
- 基于病灶18F-胆碱PET/CT汇总敏感度0.81、特异度0.92、AUC 0.98。
临床怎么用
- 对于前列腺癌分期和再分期,68Ga-PSMA PET/CT与18F-胆碱PET/CT均可考虑使用。
- 两者诊断性能无显著差异,选择时可结合示踪剂可及性等因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: PET/CT using prostate-specific membrane antigen (PSMA) and choline radiotracers is widely used for diagnosis of prostate cancer. However, the roles of and differences in diagnostic performance between these 2 radiotracers for prostate cancer are unclear. The aim of this study was to compare the staging and restaging performance of Ga-labeled PSMA and F-choline PET/CT imaging in prostate cancer. METHODS: A comprehensive search was performed in PubMed for studies reporting the staging performance of Ga-PSMA and F-choline PET/CT in prostate cancer from the inception of the database to October 1, 2018, according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses statement. Thirty-five studies were included in this systematic review and meta-analysis. Pooled estimates of patient- and lesion-based sensitivity, specificity, positive likelihood ratio (PLR), negative likelihood ratio (NLR), and diagnostic odds ratio (DOR) for Ga-PSMA and F-choline PET/CT were calculated alongside 95% confidence intervals. Summary receiver operating characteristic curves were plotted, and the area under the summary receiver operating characteristic curve (AUC) was determined alongside the Q* index. RESULTS: The patient-based overall pooled sensitivity, specificity, PLR, NLR, DOR, and AUC of Ga-PSMA PET/CT for staging in prostate cancer (13 studies) were 0.92, 0.94, 7.91, 0.14, 79.04, and 0.96, respectively, whereas those of F-choline PET/CT (16 studies) were 0.93, 0.83, 4.98, 0.10, 68.27, and 0.95. The lesion-based overall pooled sensitivity, specificity, PLR, NLR, DOR, and AUC of Ga-PSMA PET/CT for staging in prostate cancer (9 studies) were 0.83, 0.95, 23.30, 0.17, 153.58, and 0.94, respectively, and those of F-choline PET/CT (4 studies) were 0.81, 0.92, 8.59, 0.20, 44.82, and 0.98. In both patient- and lesion-based imaging, there was no statistically significant difference in the abilities of detecting or excluding prostate cancer between Ga-PSMA PET/CT and F-choline PET/CT. CONCLUSIONS: For staging and restaging performance in patients with prostate cancer, there was no significant difference between Ga-PSMA PET/CT and F-choline PET/CT. Ga-PSMA PET/CT and F-choline PET/CT have demonstrated high diagnostic performance for accurate staging and restaging in patients with prostate cancer, and thus both should be considered for staging in this disease.
引用
- Lin CY, Lee MT, Lin CL, et al. Comparing the Staging/Restaging Performance of 68Ga-Labeled Prostate-Specific Membrane Antigen and 18F-Choline PET/CT in Prostate Cancer: A Systematic Review and Meta-analysis. Clin Nucl Med. 2019. PMID: 30888999. doi:10.1097/RLU.0000000000002526
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。